{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:54:08Z","timestamp":1786586048343,"version":"build-2736575974"},"reference-count":31,"publisher":"Impact Journals, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,2,15]]},"DOI":"10.18632\/aging.202366","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T13:23:24Z","timestamp":1608384204000},"page":"3994-4006","source":"Crossref","is-referenced-by-count":8,"title":["Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by CYP2C19 metabolizer status: subgroup analysis of the PRINCE trial"],"prefix":"10.18632","volume":"13","author":[{"given":"Mengyuan","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuesong","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingquan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,12,19]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","article-title":"One-year risk of stroke after transient ischemic attack or minor stroke.","volume":"37","author":"Sissani","year":"2016","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.","volume":"36","author":"Xu","year":"2013","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack.","volume":"31","author":"Wang","year":"2016","journal-title":"JAMA"},{"key":"4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"36","author":"Sabatine","year":"2009","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.","volume":"37","author":"Becker","year":"2010","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient outcomes) PLATELET substudy.","volume":"5","author":"Wallentin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack.","volume":"37","author":"Wong","year":"2016","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1474-4422(17)30038-8","article-title":"Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.","volume":"1","author":"Wang","year":"2017","journal-title":"Lancet Neurol"},{"key":"9","doi-asserted-by":"publisher","first-page":"l2211","DOI":"10.1136\/bmj.l2211","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.","volume":"36","author":"Li","year":"2019","journal-title":"BMJ"},{"key":"10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1517\/17425250903107772","article-title":"Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.","volume":"5","author":"Tantry","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/STROKEAHA.113.000823","article-title":"CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.","volume":"4","author":"Xu","year":"2013","journal-title":"Stroke"},{"key":"12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/5584_2016_123","article-title":"Role of P2Yreceptor in thrombosis.","volume":"90","author":"Ding","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.","volume":"30","author":"Longtine","year":"2011","journal-title":"JAMA"},{"key":"14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.thromres.2014.12.007","article-title":"Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.","volume":"13","author":"Yin","year":"2015","journal-title":"Thromb Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study.","volume":"12","author":"Purdy","year":"2009","journal-title":"Circulation"},{"key":"16","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.","volume":"12","author":"Kereiakes","year":"2010","journal-title":"Circulation"},{"key":"17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijcard.2010.12.083","article-title":"The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial).","volume":"15","author":"Bozat","year":"2012","journal-title":"Int J Cardiol"},{"key":"18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.thromres.2016.01.020","article-title":"Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"13","author":"Lai","year":"2016","journal-title":"Thromb Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.","volume":"30","author":"Parsa","year":"2009","journal-title":"JAMA"},{"key":"20","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.","volume":"30","author":"Kastrati","year":"2010","journal-title":"JAMA"},{"key":"21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","article-title":"CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.","volume":"7","author":"Wiese","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M13-1999","article-title":"Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.","volume":"16","author":"Hlatky","year":"2014","journal-title":"Ann Intern Med"},{"key":"23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/STROKEAHA.116.014891","article-title":"Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).","volume":"4","author":"Johnston","year":"2017","journal-title":"Stroke"},{"key":"24","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1161\/STROKEAHA.116.016502","article-title":"Letter by moris et al regarding article, \u201cTicagrelor in acute stroke or transient ischemic attack in Asian patients: from the SOCRATES trial (acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes)\u201d.","volume":"4","author":"Avgerinos","year":"2017","journal-title":"Stroke"},{"key":"25","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1001\/jama.284.22.2901","article-title":"Short-term prognosis after emergency department diagnosis of TIA.","volume":"28","author":"Sidney","year":"2000","journal-title":"JAMA"},{"key":"26","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.","volume":"2","author":"Peters","year":"2006","journal-title":"Eur Heart J"},{"key":"27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1747493017694390","article-title":"Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: rationale and design.","volume":"1","author":"Li","year":"2017","journal-title":"Int J Stroke"},{"key":"28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3171\/2017.6.JNS17535","article-title":"Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: comparing results of the VerifyNow P2Y12 assay to thromboelastography with platelet mapping.","volume":"12","author":"Fox","year":"2018","journal-title":"J Neurosurg"},{"key":"29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.","volume":"9","author":"Shuldiner","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"30","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.","volume":"36","author":"Eikelboom","year":"2010","journal-title":"N Engl J Med"},{"key":"31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.","volume":"9","author":"Shuldiner","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T16:13:13Z","timestamp":1617725593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,19]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,15]]}},"alternative-id":["202366","33411687"],"URL":"https:\/\/doi.org\/10.18632\/aging.202366","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,19]]}}}